Avigen Board Survives Proxy Fight But Company Will Liquidate Holdings
This article was originally published in The Pink Sheet Daily
Executive Summary
In abandoning its efforts to find a buyer, troubled biotech promises shareholders a return of at least $1.20 per share.
You may also be interested in...
Frayed Deals, Fraught Partners: Product Tweaks Complicate Agreements
Sub-licenses with universities can make headaches, too, as contracts come “out of the drawer” for closer scrutiny in hard times, panelists agree at recent Napa conference.
Frayed Deals, Fraught Partners: Product Tweaks Complicate Agreements
Sub-licenses with universities can make headaches, too, as contracts come “out of the drawer” for closer scrutiny in hard times, panelists agree at recent Napa conference.
Proxy War-Front Latest: Amylin, Vanda Rocked By Dissident Shareholders
In tough times, patience for failing drugs and restructuring programs wears particularly thin.